Schrodinger Partners with Eli Lilly to Launch AI Drug Design Platform TuneLab
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: Newsfilter
- Collaborative Innovation: Schrodinger's partnership with Eli Lilly integrates Lilly's AI platform TuneLab into its LiveDesign software, enabling biotech companies to directly access this advanced tool, thereby accelerating drug development processes.
- Technological Advantage: By incorporating TuneLab into LiveDesign, chemists can more effectively design compounds and predict drug behavior in the body, enhancing the efficiency and accuracy of drug research and development.
- Market Demand: With the FDA pushing to reduce animal testing, the increasing adoption of AI by drug developers is expected to meet the urgent market demand for faster and more cost-effective drug discovery, making this collaboration timely.
- Client Expansion: Existing LiveDesign clients will gain access to TuneLab in Q1 of this year, while new users will start using it in Q2, which is anticipated to attract more biotech companies and drive diversity and speed in drug development.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1192 USD with a low forecast of 950.00 USD and a high forecast of 1500 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1032.970
Low
950.00
Averages
1192
High
1500
Current: 1032.970
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
